Literature summary for 3.4.23.16 extracted from

Lu, D.; Sham, Y.Y.; Vince, R.
Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease (2010), Bioorg. Med. Chem., 18, 2037-2048.

Search for more literature for 3.4.23.16

Inhibitors

Inhibitors	Comment	Organism	Structure
bis-[(L-valine-N-methylamide)-2-phenyl-3-yl-propionamide] sulfide	-	Human immunodeficiency virus 1
bis-[(L-valine-N-methylamide)-2-phenyl-3-yl-propionamide] sulfoxide	-	Human immunodeficiency virus 1
bis-[(L-valine-N-methylamide)-2-phenyl-3-yl-propionamide] sulfoximine	-	Human immunodeficiency virus 1
bis-[[N-(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-2S-phenyl-3-yl-propionamide] sulfoximine	-	Human immunodeficiency virus 1
bis-[[N-(2R)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfide	-	Human immunodeficiency virus 1
bis-[[N-(2R)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfoxide	-	Human immunodeficiency virus 1
bis-[[N-(2R)-phenylglycinol]-2-phenyl-3-yl-propionamide]sulfoximine	-	Human immunodeficiency virus 1
bis-[[N-(2S)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfide	-	Human immunodeficiency virus 1
bis-[[N-(2S)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfoxide	-	Human immunodeficiency virus 1
bis-[[N-(2S)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfoximine	-	Human immunodeficiency virus 1
N-methyl bis-[N-(2,2-dimethyl-8,8a-dihydro-3aH-indeno[(1S,2R)-1,2]-oxazol-3-yl) 2R-benzyl-3-yl propianamide] sulfoximine	-	Human immunodeficiency virus 1

Organism

Organism	UniProt	Comment	Textmining
Human immunodeficiency virus 1	-	-	-

Synonyms

Synonyms	Comment	Organism
HIV-1 protease	-	Human immunodeficiency virus 1

Ki Value [mM]

Ki Value [mM]	Ki Value maximum [mM]	Inhibitor	Comment	Organism	Structure
additional information	-	bis-[[N-(2S)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfide	41% inhibition at 0.01 mM	Human immunodeficiency virus 1
additional information	-	bis-[[N-(2S)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfoxide	47% inhibition at 0.01 mM	Human immunodeficiency virus 1
additional information	-	bis-[[N-(2R)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfoxide	50% inhibition at 0.01 mM	Human immunodeficiency virus 1
additional information	-	bis-[[N-(2R)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfide	51% inhibition at 0.01 mM	Human immunodeficiency virus 1
additional information	-	bis-[[N-(2R)-phenylglycinol]-2-phenyl-3-yl-propionamide]sulfoximine	54% inhibition at 0.01 mM	Human immunodeficiency virus 1
additional information	-	bis-[[N-(2S)-phenylglycinol]-2-phenyl-3-yl-propionamide] sulfoximine	87% inhibition at 0.01 mM	Human immunodeficiency virus 1
additional information	-	bis-[(L-valine-N-methylamide)-2-phenyl-3-yl-propionamide] sulfide	87% inhibition at 0.01 mM	Human immunodeficiency virus 1
additional information	-	bis-[(L-valine-N-methylamide)-2-phenyl-3-yl-propionamide] sulfoxide	90% inhibition at 0.01 mM	Human immunodeficiency virus 1
additional information	-	bis-[(L-valine-N-methylamide)-2-phenyl-3-yl-propionamide] sulfoximine	99% inhibition at 0.01 mM	Human immunodeficiency virus 1
0.0000025	-	bis-[[N-(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-2S-phenyl-3-yl-propionamide] sulfoximine	-	Human immunodeficiency virus 1
0.00046	-	N-methyl bis-[N-(2,2-dimethyl-8,8a-dihydro-3aH-indeno[(1S,2R)-1,2]-oxazol-3-yl) 2R-benzyl-3-yl propianamide] sulfoximine	-	Human immunodeficiency virus 1

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)